V iral acute respiratory infections represent a frequent complication among immunocompromised patients. Virus identification is relevant for preventive and therapeutic measures, including isolation and avoidance of unnecessary antibiotic therapies. The emergence of new respiratory viruses such as human bocavirus (HBoV) 1 in immunocompetent children raises questions regarding the significance of this newly described virus in the immunocompromised host.
In the present study, various respiratory samples were collected from immunocompromised pediatric patients treated at our institution in a 3-year period (2004 -2007) , whenever new respiratory symptoms occurred. The respiratory samples-together with nonrespiratory specimens (ie, plasma and feces) collected for other medical reasons around the time when respiratory symptoms began-were retrospectively screened by quantitative real-time polymerase chain reaction (PCR) for HBoV DNA. 2 Patients' charts were reviewed for relevant clinical data. Additionally, all respiratory specimens were screened for other respiratory viruses by multiplex PCR, using the ID-TAG Respiratory Viral Panel (TM Bioscience Corporation, Toronto, ON). 3 PCRs were performed prospectively on plasma samples for the detection of Epstein Barr virus (EBV) and cytomegalovirus (CMV). In total, 135 separate respiratory episodes occurring in 69 immunocompromised patients were included. In the present study, we describe 4 cases in which HBoV DNA was repeatedly detected during a prolonged period.
CASE REPORTS
Case 1. A 2-year-old girl with severe combined immunodeficiency syndrome was hospitalized in July 2004 with an EBV-associated B-cell lymphoma and active EBV infection. She presented with fever, lymphadenopathy, and mucosal infiltrates. Her general condition improved with rituximab and cidofovir treatment. Transplantation of allogenic hematopoietic stem cells (HSC) from an EBV-positive donor was planned. A reduced conditioning protocol (thiotepa, 5 mg/kg; fludarabine, 40 mg/m 2 ; and ATG) was adopted. With this regimen, the EBV DNA load declined from 153,000 to 7000 copies/mL and later was negative. However, the patient was severely granulocytopenic, and developed pulmonary aspergillosis. Pulmonary symptoms continued to deteriorate, despite aggressive antimicrobial and antifungal therapy. At this time, a nasopharyngeal aspirate (NPA), and 2 plasma samples taken 1 day before and 4 days thereafter, tested positive for HBoV (Fig. 1) . Coinfection with rhinovirus was assessed by multiplex PCR. 3 A lung biopsy confirmed invasive aspergillosis with focal and intraalveolar bleeding and it also harbored HBoV DNA (Fig. 1) . The patient
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The Pediatric Infectious Disease Journal • Volume 30, Number 1, January 2011 eventually died of acute pulmonary decompensation and generalized capillary leakage. Case 2. An 8-month-old EBV-positive boy with hemophagocytic lymphohistiocytosis was admitted to the bone marrow transplantation unit in July 2006. Treatment with cyclosporine A and steroids resulted in an increase of EBV DNA load from 518 to 9450 copies/mL in whole blood. The patient was treated with rituximab. At this time point, he also developed respiratory symptoms (tachypnea and supplemental oxygen requirement) with fever. Chest radiography showed lung infiltrates in the basal lower lobes. Two NPAs obtained at the beginning of the respiratory symptoms harbored high load of HBoV DNA (5 ϫ 10 12 and 7 ϫ 10 9 copies/mL). Codetection of rhinovirus and human coronavirus NL63 RNA was assessed by multiplex PCR. 3 Viremia with low HBoV DNA load (1 ϫ 10 2 and 2.3 ϫ 10 3 copies /mL) was observed before (ie, day 11 and day 3) but not after HBoV detection in NPA (Fig. 1) . The peak of HBoV DNA load in the respiratory tract was concomitant to EBV reactivation. The patient recovered, and subsequent serum samples and NPA were negative for HBoV DNA. Two weeks later, the patient underwent HSC transplantation and died of hepatic veno-occlusive disease. Case 3. An 18-year-old boy with myelodysplastic syndrome and a history of HSC transplantation, completed 2 years previously, was hospitalized in March 2007 for acute respiratory symptoms. He presented with fever, productive cough, and tachypnea. Peribronchial infiltrates were evident on chest radiograph. The patient was under intensive immunosuppression to treat chronic GvHD of skin and mucosa. A bronchoalveolar lavage (BAL) and a serum sample taken at this time point were retrospectively tested for the presence of HBoV. The samples revealed extremely high DNA load in the BAL (Ͼ10 15 copies/mL) and relatively high load (4.7 ϫ 10 7 copies /mL) in plasma. Additionally, the BAL sample was positive for PIV-3 in the multiplex PCR. 3 Microbiologic analysis of the BAL revealed the presence of extended-spectrum beta-lactamaseproducing Escherichia coli and Aspergillus fumigatus, as well as Pneumocystis jirovecii DNA, although no cysts were detected. Antifungal and antibacterial therapy was started and the patient's general condition improved. Later serum samples as well as an NPA and a stool sample were negative for HBoV (Fig. 1) . The patient also had chronic sinusitis, and 5 months later underwent surgery for suspected aspergilloma. However, this diagnosis was not confirmed and microbiologic analysis of the sphenoid sinus biopsy and exudates was negative for the presence of fungi. Analyses of both materials for the presence of respiratory viruses revealed HBoV as the sole agent in the biopsy and HBoV and rhinovirus in the exudate. No NPA was available at the time of testing. Partial sequencing of the VP1 gene of HBoV from BAL, plasma, and sphenoid sinus samples was performed as described, 4 and revealed 100% identity. This finding is in accordance with persistence of the same HBoV strain over a 5-month period. Case 4. A 4-year-old boy with dyskeratosis congenita developed pneumonia with perihilar infiltrates 17 days after HSCT. Repeat detection of high HBoV DNA load in NPA during a 2-month period with codetection of rhinovirus, which was accompanied by HBoV viremia and prolonged HBoV shedding (3 months) in the feces even after resolution of respiratory symptoms, has already been reported in detail. 5 As described previously, the patient showed a simultaneous CMV reactivation concomitant to the peak in HBoV load in NPS. 5 Partial sequencing of the VP1 gene of HBoV DNA obtained from the different samples was performed as described, 4 and revealed 100% identity, suggesting persistence of the same HBoV strain.
DISCUSSION
The present study shows that HBoV can be detected at moderate to high viral loads in samples from immunocompromised patients with underlying hematologic diseases or primary immunodeficiencies undergoing HSC transplantation. Previous studies have shown that prolonged HBoV shedding can be observed during immunosuppression, which possibly indicate persistence and/or reactivation in these patients. 5, 6 A recent work also shows prolonged detection of HBoV in immunocompetent children with respiratory tract disease. 7 In the 4 cases described in this study, we repeatedly detected HBoV DNA in the respiratory tract and/or in plasma, and in one case also in the gastrointestinal tract, for a period of up to 5 months. In all cases, HBoV replication in the respiratory tract was accompanied by viremia. However, the clinical relevance of prolonged detection of HBoV in respiratory samples and plasma is 
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Bocavirus in the Immunocompromised unclear. Failure of the immune system in all 4 cases was characterized by severe granulocytopenia (below 500 granulocytes/L) and/or impairment of both the T-cell and the B-cell compartment with opportunistic infection (aspergillosis) in case 1, EBV reactivation in case 2, aspergillosis and P. jirovecii infection in case 3, and CMV reactivation in case 4. This strongly indicates that severe immunodeficiency may lead to high levels of HBoV replication. Detection of HBoV in the lung biopsy of patient 1 should be interpreted with caution, because HBoV DNA was detected at the same time point in plasma, and we cannot exclude blood contamination of lung biopsy. Most intriguing was the detection of HBoV DNA in a sphenoid sinus biopsy 5 months after detection of more than 10 15 and 10 7 copies/mL in BAL and in plasma, respectively, in the absence of HBoV DNA in blood. HBoV may have played a role in the pathogenesis of chronic sinusitis in this case; alternatively, the mucosal tissue of nasal sinuses may represent a site of HBoV persistence after high-level replication in the respiratory tract. Similarly, recent findings have suggested that HBoV may establish persistent infections of mucosal lymphocytes and/or contribute to tonsillar hyperplasia in children. 8 Further investigations, with appropriate matched controls, are needed to understand the bystander or causative role of HBoV in chronic sinusitis in immunocompromised and immunocompetent patients.
In cases 1, 2, and 4, HBoV was detected during the late spring and summer months, whereas HBoV infections in immunocompetent patients predominantly have been described to occur during the winter season, and only rarely in spring or summer. 4 This observation, together with the fact that in these cases HBoV was detected after 3 to 5 weeks of strict isolation, further favors the hypothesis of reactivation of persistent HBoV infection during immunosuppression. Although it cannot be excluded, nosocomial infection appears to be less likely because of general prevention measures. The patient described in case 3 was 18 years old. Recent seroepidemiologic data suggest that antibodies to HBoV are present in more than 90% of children at the age of 6 years, 9 which makes primary infection in this patient unlikely. Moreover, sequence identity of HBoV DNA from samples taken 5 months apart was detected by partial sequencing of a region of the VP1 gene (819 nucleotides) known to display the greatest frequency of nucleotide polymorphisms. 4 This finding, further supported by identity of HBoV sequences in subsequent samples from a second patient (case 4), is compatible with persistent infection.
We found coinfections with one or more viruses in all 4 cases. A high frequency of codetection is a significant feature of HBoV and may argue against its causative role in respiratory infections. Moreover, Esposito et al 10 have recently shown that the clinical impact of HBoV in infected children may become significant when it is present together with other viruses. Potentially, HBoV may act as an exacerbating factor increasing the severity of infections caused by other pathogens.
Apart from the unsolved question of pathogenicity, our observations suggest the following 2 possibilities: (i) HBoV may be able to persist at low levels in the setting of an efficient immune system, thus making its detection difficult unless an immunocompromised status and/or coinfection with other viruses and subsequent increased replication occur; (ii) exposure to HBoV during immunosuppression can lead to persistent infection and prolonged viral shedding.
